Vanguard urged to liquidate
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.VANGUARD MEDICA, the troubled biotechnology group, was in fresh turmoil yesterday when a shareholder urged the board to liquidate the company and return pounds 96m to investors.
Paul Mc Groary, a professional investor with a small stake in Vanguard, said in a letter to the chief executive, Robert Mansfield, that he had been "dismayed" at the company's recent performance. Setbacks for its star migraine drug had caused a plunge in the share price and made Vanguard "extremely vulnerable" to takeover.
Vanguard shares have lost more than a third of their value since their April peak. Yesterday they closed down 1p at 194p.
Mr Mc Groary said the board should discontinue all projects apart from the migraine drug, cut staff and costs and return pounds 3 per share to shareholders, or Vanguard should be "made available as a virtual cash shell to a biotech company".
It is understood Mr Mc Groary has contacted three biotech groups which might be interested in buying Vanguard.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments